This award recognises a private CEO that has demonstrated truly outstanding and exemplary leadership of a privately-owned life science company. This category is a peer-to-peer award with votes having originated from the attending executives. As this is a joint award, there will be both an EU and US winner in this category.
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.